Neurovascular Intervention Devices Market by Product Type (Embolic Agents, Flow Diverters, Microcatheters), Indication (Aneurysm, Arteriovenous Malformation, Stroke), Procedure Type, End User - Global Forecast 2025-2032
Description
The Neurovascular Intervention Devices Market was valued at USD 4.25 billion in 2024 and is projected to grow to USD 4.53 billion in 2025, with a CAGR of 6.69%, reaching USD 7.14 billion by 2032.
A comprehensive introduction situating neurovascular intervention devices within clinical demand, innovation trajectory, and evolving care delivery imperatives
Neurovascular intervention devices are situated at the intersection of acute clinical need and rapid technological advancement. Over the past decade clinicians and device developers have converged on minimally invasive approaches that prioritize vessel preservation, rapid reperfusion, and durable aneurysm occlusion. As a result, treatment paradigms have shifted away from open surgery toward endovascular therapies that reduce perioperative risk and shorten recovery times. This introductory review frames the broader context in which device design, procedural training, and value-based procurement decisions are evolving.
In parallel, improvements in imaging modalities, catheter technology, and embolic materials have expanded the range of anatomies that can be treated safely. Consequently, health systems increasingly evaluate devices not only on acute clinical outcomes but also on workflow integration, total procedural time, and long-term durability. Regulatory pathways and post-market surveillance are adapting to support iterative device improvements while maintaining patient safety. With this context established, the following sections explore the transformative shifts shaping clinical adoption, the implications of tariff developments, segmentation insights that inform supplier strategies, regional dynamics, leading company behaviors, pragmatic recommendations for industry leaders, and the research approach used to compile this analysis.
An examination of the transformative clinical, technological, and commercial shifts redefining neurovascular intervention practice and supplier models
The landscape of neurovascular interventions is undergoing transformative shifts driven by convergent advances in materials science, device engineering, and procedural technique. Flow diversion and refined embolic chemistries have expanded therapeutic choices for complex aneurysms, while aspiration systems and stent retrievers have redefined acute ischemic stroke care by enabling faster, more effective reperfusion. Alongside device innovation, there is growing emphasis on systems-level integration that reduces door-to-reperfusion times and improves coordination across pre-hospital, emergency, and interventional teams.
Commercially, manufacturers are responding with integrated offerings that bundle devices, consumables, and digital tools for planning and outcome tracking. This vertical integration is paralleled by increased collaboration between clinicians and R&D teams, accelerating iterative improvements. Moreover, regulatory authorities are emphasizing real-world evidence and post-market registries to monitor long-term safety and durability, prompting suppliers to design studies that capture longitudinal outcomes. Taken together, these shifts underscore a transition from device-centric sales toward evidence-led partnerships with health systems, and they create opportunities for companies that can demonstrate meaningful clinical and operational value.
A focused analysis of how United States tariff changes in 2025 are reshaping procurement strategies, supply chain resilience, and manufacturing footprint decisions
Changes in trade policy and tariff regimes in the United States in 2025 have introduced new considerations for manufacturers and health systems that source neurovascular intervention devices globally. For firms that rely on cross-border supply chains, tariff adjustments can alter component sourcing economics and influence decisions about local manufacturing, supplier consolidation, and inventory strategies. In response, procurement teams are reassessing total landed costs, factoring in potential customs duties, lead time variability, and the administrative burden associated with compliance.
From a strategic perspective, manufacturers are evaluating whether to absorb additional costs, pass them on through pricing adjustments, or reconfigure production footprints to mitigate exposure. This environment is also prompting renewed attention to supplier diversification and nearshoring to maintain resilience. Clinically, hospitals and integrated delivery networks are balancing the desire for best-in-class devices with the need for predictable supply contracts and budgetary stability. Consequently, stakeholders are placing increased value on transparent contractual terms, long-term agreements with contingency provisions, and collaborative forecasting practices to reduce disruption risk while preserving access to the devices that support high-quality neurovascular care.
Actionable segmentation insights across product, indication, end user, and procedure type that clarify development priorities and commercialization pathways
Segment-level understanding is essential for stakeholders who must prioritize development, commercialization, and clinical adoption efforts. When the market is examined by product type, the portfolio ranges from embolic agents - which include both liquid embolics and particulate embolics - to flow diverters that encompass devices such as dedicated pipeline embolization solutions and alternative flow diversion systems. Microcatheter choices vary by coating technologies, with hydrophilic coated and polymer coated variants influencing navigability and compatibility. Neurovascular coils are differentiated into detachable coils and pushable coils, while stents are available as balloon mounted or self expanding options. Thrombectomy devices complete the procedural toolkit, represented by aspiration devices and stent retriever systems. These product distinctions have implications for clinical training needs, inventory management, and incremental R&D priorities.
In terms of clinical indication, the primary applications include aneurysm treatment, management of arteriovenous malformation, and acute stroke intervention. Each indication drives different product requirements, regulatory evidence expectations, and procedural workflows. For end users, the landscape spans ambulatory centers, clinics, and hospitals; adoption dynamics differ significantly between outpatient interventional suites and tertiary care centers that handle high-acuity stroke cases. Finally, procedure type stratification into embolization, flow diversion, and thrombectomy highlights pathway-specific device combinations and peri-procedural resource implications. Integrating these segmentation lenses enables companies to tailor go-to-market strategies, refine clinician training programs, and design value propositions that align with specific clinical and operational constraints.
Regional market dynamics and clinical ecosystem differences that influence device adoption, regulatory approaches, and strategic market entry decisions
Regional dynamics materially influence clinical practice patterns, regulatory expectations, and commercial opportunity for neurovascular intervention devices. In the Americas, established stroke systems of care and well-resourced tertiary centers support rapid adoption of advanced thrombectomy systems and high-end flow diverters, while procurement constraints in smaller centers drive interest in cost-effective consumables and streamlined procedural kits. Transitioning to Europe, Middle East & Africa, heterogeneity in regulatory frameworks and reimbursement pathways results in variable adoption rates; strategic partnerships with local distributors and targeted evidence generation are often necessary to achieve scale in these markets. In the Asia-Pacific region, rising investment in stroke networks, expanding interventional capacity, and growing domestic manufacturing capabilities are creating a dynamic environment where both global innovators and regional players compete for market leadership.
Across all regions, key differentiators include the maturity of emergency medical services, the density of trained neurointerventionalists, and the structure of payer systems. Consequently, companies that align their market entry models with local clinical workflows, regulatory timelines, and procurement practices are more likely to secure durable adoption. Moreover, region-specific investments in clinician training, registry participation, and health-economic data generation can accelerate acceptance by demonstrating contextual value to hospitals and health systems.
Key company behaviors and competitive strategies that combine device innovation, clinical evidence generation, and ecosystem partnerships to accelerate adoption
Company behavior in the neurovascular devices space reflects a dual focus on technological differentiation and strategic partnerships. Leading manufacturers are investing in next-generation flow diversion platforms, advanced thrombectomy architectures, and embolic chemistries designed to improve deliverability and long-term occlusion. At the same time, several firms are expanding service offerings around procedural planning software, simulation-based training, and registry-driven evidence generation to deepen clinical engagement. Strategic collaborations with imaging companies and robotics developers are emerging as companies seek to integrate devices into broader interoperability ecosystems.
Competitive dynamics also show an emphasis on lifecycle management of existing product families through iterative improvements to coatings, catheter compatibility, and ease-of-use features. Additionally, some companies pursue geographic expansion via distribution agreements and localized manufacturing partnerships to address procurement sensitivity and regulatory variation. Across the board, successful players combine clinical data generation with practical support for procedural adoption, such as hands-on training programs and post-market outcome tracking, thereby building credibility with influential clinical centers and payers.
Actionable recommendations for manufacturers and clinical leaders to align innovation, evidence, and supply strategies with health system priorities
Industry leaders should prioritize actions that align product development with clinical workflow needs and system-level outcomes. First, invest in evidence generation that extends beyond acute procedural success to include measures of functional recovery, reintervention rates, and resource utilization; this broader evidence base strengthens conversations with payers and hospital procurement teams. Second, design device portfolios and supply models that address both high-acuity tertiary centers and resource-constrained community settings by offering adaptable kits and flexible contracting terms. Third, pursue partnerships that improve interoperability with imaging and digital planning tools, thereby reducing friction during case preparation and execution.
Further, supply chain resilience must be elevated as a strategic priority through diversified sourcing, nearshoring where appropriate, and collaborative forecasting with major health system customers. In parallel, commit to scalable clinician education programs that combine simulation, proctorship, and digital learning to accelerate safe adoption. Finally, deploy pragmatic value communication frameworks that translate clinical benefits into operational metrics such as procedure time, length of stay, and post-procedural resource needs so decision-makers can assess total system impact consistently.
A transparent research methodology combining clinical guideline review, expert interviews, regulatory analysis, and cross-validated synthesis to ensure robust insights
The research approach underpinning this analysis combines structured literature review, expert interviews, and synthesis of public regulatory and clinical guidance to ensure findings reflect contemporary practice and policy. Peer-reviewed clinical studies and procedural guidelines informed the clinical framing, while interviews with interventionalists, procurement leads, and regulatory specialists provided practical insights into adoption barriers and operational constraints. Regulatory documents and payer communications were examined to identify evolving evidence expectations and reimbursement considerations that influence commercialization timelines.
To enhance validity, the analysis triangulated clinician perspectives with industry disclosures and publicly available post-market registries. The methodology emphasized cross-validation to reduce bias, and findings were iteratively reviewed by subject-matter experts to ensure clinical relevance. Where uncertainty remained, the report highlights areas that require targeted primary data collection or focused registries, thereby guiding subsequent evidence-generation priorities for sponsors and health systems.
A conclusive synthesis of device innovation, clinical adoption dynamics, regional variation, and strategic priorities for durable market impact
In conclusion, neurovascular intervention devices occupy a rapidly evolving space where clinical urgency, technological innovation, and system-level priorities converge. Advances across embolic agents, flow diversion technologies, microcatheters, coils, stents, and thrombectomy systems are expanding treatment options and improving patient outcomes, while also introducing complexity in procurement and training. Regional differences in health system maturity and regulatory frameworks underscore the need for tailored market strategies, and recent tariff and supply chain developments emphasize resilience and localized planning.
Moving forward, companies that integrate rigorous clinical evidence, pragmatic clinician support, and resilient supply models will be best positioned to influence standards of care. Collaboration between industry, clinicians, and health systems to generate relevant outcomes data and to streamline procedural workflows will accelerate adoption of technologies that deliver clear patient and operational value. Stakeholders should therefore prioritize actions that balance innovation with demonstrable system-level benefits to ensure sustainable progress in neurovascular care.
Please Note: PDF & Excel + Online Access - 1 Year
A comprehensive introduction situating neurovascular intervention devices within clinical demand, innovation trajectory, and evolving care delivery imperatives
Neurovascular intervention devices are situated at the intersection of acute clinical need and rapid technological advancement. Over the past decade clinicians and device developers have converged on minimally invasive approaches that prioritize vessel preservation, rapid reperfusion, and durable aneurysm occlusion. As a result, treatment paradigms have shifted away from open surgery toward endovascular therapies that reduce perioperative risk and shorten recovery times. This introductory review frames the broader context in which device design, procedural training, and value-based procurement decisions are evolving.
In parallel, improvements in imaging modalities, catheter technology, and embolic materials have expanded the range of anatomies that can be treated safely. Consequently, health systems increasingly evaluate devices not only on acute clinical outcomes but also on workflow integration, total procedural time, and long-term durability. Regulatory pathways and post-market surveillance are adapting to support iterative device improvements while maintaining patient safety. With this context established, the following sections explore the transformative shifts shaping clinical adoption, the implications of tariff developments, segmentation insights that inform supplier strategies, regional dynamics, leading company behaviors, pragmatic recommendations for industry leaders, and the research approach used to compile this analysis.
An examination of the transformative clinical, technological, and commercial shifts redefining neurovascular intervention practice and supplier models
The landscape of neurovascular interventions is undergoing transformative shifts driven by convergent advances in materials science, device engineering, and procedural technique. Flow diversion and refined embolic chemistries have expanded therapeutic choices for complex aneurysms, while aspiration systems and stent retrievers have redefined acute ischemic stroke care by enabling faster, more effective reperfusion. Alongside device innovation, there is growing emphasis on systems-level integration that reduces door-to-reperfusion times and improves coordination across pre-hospital, emergency, and interventional teams.
Commercially, manufacturers are responding with integrated offerings that bundle devices, consumables, and digital tools for planning and outcome tracking. This vertical integration is paralleled by increased collaboration between clinicians and R&D teams, accelerating iterative improvements. Moreover, regulatory authorities are emphasizing real-world evidence and post-market registries to monitor long-term safety and durability, prompting suppliers to design studies that capture longitudinal outcomes. Taken together, these shifts underscore a transition from device-centric sales toward evidence-led partnerships with health systems, and they create opportunities for companies that can demonstrate meaningful clinical and operational value.
A focused analysis of how United States tariff changes in 2025 are reshaping procurement strategies, supply chain resilience, and manufacturing footprint decisions
Changes in trade policy and tariff regimes in the United States in 2025 have introduced new considerations for manufacturers and health systems that source neurovascular intervention devices globally. For firms that rely on cross-border supply chains, tariff adjustments can alter component sourcing economics and influence decisions about local manufacturing, supplier consolidation, and inventory strategies. In response, procurement teams are reassessing total landed costs, factoring in potential customs duties, lead time variability, and the administrative burden associated with compliance.
From a strategic perspective, manufacturers are evaluating whether to absorb additional costs, pass them on through pricing adjustments, or reconfigure production footprints to mitigate exposure. This environment is also prompting renewed attention to supplier diversification and nearshoring to maintain resilience. Clinically, hospitals and integrated delivery networks are balancing the desire for best-in-class devices with the need for predictable supply contracts and budgetary stability. Consequently, stakeholders are placing increased value on transparent contractual terms, long-term agreements with contingency provisions, and collaborative forecasting practices to reduce disruption risk while preserving access to the devices that support high-quality neurovascular care.
Actionable segmentation insights across product, indication, end user, and procedure type that clarify development priorities and commercialization pathways
Segment-level understanding is essential for stakeholders who must prioritize development, commercialization, and clinical adoption efforts. When the market is examined by product type, the portfolio ranges from embolic agents - which include both liquid embolics and particulate embolics - to flow diverters that encompass devices such as dedicated pipeline embolization solutions and alternative flow diversion systems. Microcatheter choices vary by coating technologies, with hydrophilic coated and polymer coated variants influencing navigability and compatibility. Neurovascular coils are differentiated into detachable coils and pushable coils, while stents are available as balloon mounted or self expanding options. Thrombectomy devices complete the procedural toolkit, represented by aspiration devices and stent retriever systems. These product distinctions have implications for clinical training needs, inventory management, and incremental R&D priorities.
In terms of clinical indication, the primary applications include aneurysm treatment, management of arteriovenous malformation, and acute stroke intervention. Each indication drives different product requirements, regulatory evidence expectations, and procedural workflows. For end users, the landscape spans ambulatory centers, clinics, and hospitals; adoption dynamics differ significantly between outpatient interventional suites and tertiary care centers that handle high-acuity stroke cases. Finally, procedure type stratification into embolization, flow diversion, and thrombectomy highlights pathway-specific device combinations and peri-procedural resource implications. Integrating these segmentation lenses enables companies to tailor go-to-market strategies, refine clinician training programs, and design value propositions that align with specific clinical and operational constraints.
Regional market dynamics and clinical ecosystem differences that influence device adoption, regulatory approaches, and strategic market entry decisions
Regional dynamics materially influence clinical practice patterns, regulatory expectations, and commercial opportunity for neurovascular intervention devices. In the Americas, established stroke systems of care and well-resourced tertiary centers support rapid adoption of advanced thrombectomy systems and high-end flow diverters, while procurement constraints in smaller centers drive interest in cost-effective consumables and streamlined procedural kits. Transitioning to Europe, Middle East & Africa, heterogeneity in regulatory frameworks and reimbursement pathways results in variable adoption rates; strategic partnerships with local distributors and targeted evidence generation are often necessary to achieve scale in these markets. In the Asia-Pacific region, rising investment in stroke networks, expanding interventional capacity, and growing domestic manufacturing capabilities are creating a dynamic environment where both global innovators and regional players compete for market leadership.
Across all regions, key differentiators include the maturity of emergency medical services, the density of trained neurointerventionalists, and the structure of payer systems. Consequently, companies that align their market entry models with local clinical workflows, regulatory timelines, and procurement practices are more likely to secure durable adoption. Moreover, region-specific investments in clinician training, registry participation, and health-economic data generation can accelerate acceptance by demonstrating contextual value to hospitals and health systems.
Key company behaviors and competitive strategies that combine device innovation, clinical evidence generation, and ecosystem partnerships to accelerate adoption
Company behavior in the neurovascular devices space reflects a dual focus on technological differentiation and strategic partnerships. Leading manufacturers are investing in next-generation flow diversion platforms, advanced thrombectomy architectures, and embolic chemistries designed to improve deliverability and long-term occlusion. At the same time, several firms are expanding service offerings around procedural planning software, simulation-based training, and registry-driven evidence generation to deepen clinical engagement. Strategic collaborations with imaging companies and robotics developers are emerging as companies seek to integrate devices into broader interoperability ecosystems.
Competitive dynamics also show an emphasis on lifecycle management of existing product families through iterative improvements to coatings, catheter compatibility, and ease-of-use features. Additionally, some companies pursue geographic expansion via distribution agreements and localized manufacturing partnerships to address procurement sensitivity and regulatory variation. Across the board, successful players combine clinical data generation with practical support for procedural adoption, such as hands-on training programs and post-market outcome tracking, thereby building credibility with influential clinical centers and payers.
Actionable recommendations for manufacturers and clinical leaders to align innovation, evidence, and supply strategies with health system priorities
Industry leaders should prioritize actions that align product development with clinical workflow needs and system-level outcomes. First, invest in evidence generation that extends beyond acute procedural success to include measures of functional recovery, reintervention rates, and resource utilization; this broader evidence base strengthens conversations with payers and hospital procurement teams. Second, design device portfolios and supply models that address both high-acuity tertiary centers and resource-constrained community settings by offering adaptable kits and flexible contracting terms. Third, pursue partnerships that improve interoperability with imaging and digital planning tools, thereby reducing friction during case preparation and execution.
Further, supply chain resilience must be elevated as a strategic priority through diversified sourcing, nearshoring where appropriate, and collaborative forecasting with major health system customers. In parallel, commit to scalable clinician education programs that combine simulation, proctorship, and digital learning to accelerate safe adoption. Finally, deploy pragmatic value communication frameworks that translate clinical benefits into operational metrics such as procedure time, length of stay, and post-procedural resource needs so decision-makers can assess total system impact consistently.
A transparent research methodology combining clinical guideline review, expert interviews, regulatory analysis, and cross-validated synthesis to ensure robust insights
The research approach underpinning this analysis combines structured literature review, expert interviews, and synthesis of public regulatory and clinical guidance to ensure findings reflect contemporary practice and policy. Peer-reviewed clinical studies and procedural guidelines informed the clinical framing, while interviews with interventionalists, procurement leads, and regulatory specialists provided practical insights into adoption barriers and operational constraints. Regulatory documents and payer communications were examined to identify evolving evidence expectations and reimbursement considerations that influence commercialization timelines.
To enhance validity, the analysis triangulated clinician perspectives with industry disclosures and publicly available post-market registries. The methodology emphasized cross-validation to reduce bias, and findings were iteratively reviewed by subject-matter experts to ensure clinical relevance. Where uncertainty remained, the report highlights areas that require targeted primary data collection or focused registries, thereby guiding subsequent evidence-generation priorities for sponsors and health systems.
A conclusive synthesis of device innovation, clinical adoption dynamics, regional variation, and strategic priorities for durable market impact
In conclusion, neurovascular intervention devices occupy a rapidly evolving space where clinical urgency, technological innovation, and system-level priorities converge. Advances across embolic agents, flow diversion technologies, microcatheters, coils, stents, and thrombectomy systems are expanding treatment options and improving patient outcomes, while also introducing complexity in procurement and training. Regional differences in health system maturity and regulatory frameworks underscore the need for tailored market strategies, and recent tariff and supply chain developments emphasize resilience and localized planning.
Moving forward, companies that integrate rigorous clinical evidence, pragmatic clinician support, and resilient supply models will be best positioned to influence standards of care. Collaboration between industry, clinicians, and health systems to generate relevant outcomes data and to streamline procedural workflows will accelerate adoption of technologies that deliver clear patient and operational value. Stakeholders should therefore prioritize actions that balance innovation with demonstrable system-level benefits to ensure sustainable progress in neurovascular care.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
188 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of flow diversion devices for complex intracranial aneurysm treatment improving long-term occlusion rates
- 5.2. Advances in biodegradable embolic materials reducing risk of chronic inflammation and aiding vessel remodeling
- 5.3. Integration of real-time robotic-assisted neurovascular navigation systems enhancing procedural precision and safety
- 5.4. Development of next-generation thin-walled stents for improved vessel conformability and reduced thrombogenicity
- 5.5. Implementation of artificial intelligence-driven imaging analytics for optimized endovascular procedure planning
- 5.6. Rise in demand for microcatheters with improved torque control to navigate tortuous cerebral vasculature effectively
- 5.7. Expansion of hybrid operating room suites combining CT angiography and fluoroscopy to streamline neurointerventions
- 5.8. Growth in minimally invasive liquid embolic agents enabling targeted vascular occlusion with lower risk profiles
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Neurovascular Intervention Devices Market, by Product Type
- 8.1. Embolic Agents
- 8.1.1. Liquid Embolics
- 8.1.2. Particulate Embolics
- 8.2. Flow Diverters
- 8.2.1. Pipeline Embolization Device
- 8.2.2. Surpass Flow Diverter
- 8.3. Microcatheters
- 8.3.1. Hydrophilic Coated
- 8.3.2. Polymer Coated
- 8.4. Neurovascular Coils
- 8.4.1. Detachable Coils
- 8.4.2. Pushable Coils
- 8.5. Stents
- 8.5.1. Balloon Mounted
- 8.5.2. Self Expanding
- 8.6. Thrombectomy Devices
- 8.6.1. Aspiration Devices
- 8.6.2. Stent Retriever
- 9. Neurovascular Intervention Devices Market, by Indication
- 9.1. Aneurysm
- 9.2. Arteriovenous Malformation
- 9.3. Stroke
- 10. Neurovascular Intervention Devices Market, by Procedure Type
- 10.1. Embolization
- 10.2. Flow Diversion
- 10.3. Thrombectomy
- 11. Neurovascular Intervention Devices Market, by End User
- 11.1. Ambulatory Centers
- 11.2. Clinics
- 11.3. Hospitals
- 12. Neurovascular Intervention Devices Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Neurovascular Intervention Devices Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Neurovascular Intervention Devices Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Stryker Corporation
- 15.3.2. Medtronic plc
- 15.3.3. Johnson & Johnson Services, Inc.
- 15.3.4. Penumbra, Inc.
- 15.3.5. Boston Scientific Corporation
- 15.3.6. Terumo Corporation
- 15.3.7. Becton, Dickinson and Company
- 15.3.8. MicroPort Scientific Corporation
- 15.3.9. MicroVention, Inc.
- 15.3.10. Kaneka Corporation
- 15.3.11. Abbott Laboratories
- 15.3.12. Acandis GmbH
- 15.3.13. Balt Group
- 15.3.14. Evasc Medical Systems Corp.
- 15.3.15. GE Healthcare
- 15.3.16. Imperative Care Inc.
- 15.3.17. Japan Lifeline Co.
- 15.3.18. Koninklijke Philips N.V.
- 15.3.19. LivaNova PLC
- 15.3.20. Medikit Co., Ltd.
- 15.3.21. Nanoflex Robotics AG
- 15.3.22. Phenox GmbH by Wallaby Medical, LLC
- 15.3.23. Rapid Medical Ltd.
- 15.3.24. Carl Zeiss AG
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
